These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65 related articles for article (PubMed ID: 6661742)
21. Substance P and vasoactive intestinal polypeptide but not calcitonin gene-related peptide concentrations are reduced in patients with moderate and severe ulcerative colitis. Renzi D; Mantellini P; Calabrò A; Panerai C; Amorosi A; Paladini I; Salvadori G; Garcea MR; Surrenti C Ital J Gastroenterol Hepatol; 1998 Feb; 30(1):62-70. PubMed ID: 9615269 [TBL] [Abstract][Full Text] [Related]
22. Diagnostic problems and advances in inflammatory bowel disease. Odze R Mod Pathol; 2003 Apr; 16(4):347-58. PubMed ID: 12692200 [TBL] [Abstract][Full Text] [Related]
23. Plasma and mucosal prostaglandin E2 as a surrogate marker of ulcerative colitis activity. Wiercińska-Drapało A; Flisiak R; Prokopowicz D Rocz Akad Med Bialymst; 2001; 46():60-8. PubMed ID: 11780581 [TBL] [Abstract][Full Text] [Related]
24. Antitumor activity and some immunological properties of gammadelta T-cells from patients with gastrointestinal carcinomas. Murayama M; Tanaka Y; Yagi J; Uchiyama T; Ogawa K Anticancer Res; 2008; 28(5B):2921-31. PubMed ID: 19031935 [TBL] [Abstract][Full Text] [Related]
25. Clinical and pathomorphological findings in patients with colorectal carcinoma complicating ulcerative colitis. Schneider A; Stolte M Z Gastroenterol; 1993 Mar; 31(3):192-7. PubMed ID: 8386413 [TBL] [Abstract][Full Text] [Related]
26. Gastrointestinal tract pathology in patients with common variable immunodeficiency (CVID): a clinicopathologic study and review. Daniels JA; Lederman HM; Maitra A; Montgomery EA Am J Surg Pathol; 2007 Dec; 31(12):1800-12. PubMed ID: 18043034 [TBL] [Abstract][Full Text] [Related]
27. Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease. Folwaczny C; Wiebecke B; Loeschke K Am J Gastroenterol; 1999 Jun; 94(6):1551-5. PubMed ID: 10364024 [TBL] [Abstract][Full Text] [Related]
28. K-ras mutations and p53 alterations in neoplastic and nonneoplastic lesions associated with longstanding ulcerative colitis. Chaubert P; Benhattar J; Saraga E; Costa J Am J Pathol; 1994 Apr; 144(4):767-75. PubMed ID: 8160776 [TBL] [Abstract][Full Text] [Related]
29. Colectomy rate in acute severe ulcerative colitis in the infliximab era. Aratari A; Papi C; Clemente V; Moretti A; Luchetti R; Koch M; Capurso L; Caprilli R Dig Liver Dis; 2008 Oct; 40(10):821-6. PubMed ID: 18472316 [TBL] [Abstract][Full Text] [Related]
30. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies). National Toxicology Program Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653 [TBL] [Abstract][Full Text] [Related]
31. Transforming growth factor beta1 and prostaglandin E2 concentrations are associated with bone formation markers in ulcerative colitis patients. Wiercinska-Drapalo A; Jaroszewicz J; Tarasow E; Flisiak R; Prokopowicz D Prostaglandins Other Lipid Mediat; 2005 Dec; 78(1-4):160-8. PubMed ID: 16303613 [TBL] [Abstract][Full Text] [Related]
32. [Risk factors for ulcerative colitis associated colorectal cancers in a Hungarian cohort of ulcerative colitis patients]. Lakatos L; Mester G; Erdélyi Z; David G; Pandúr T; Balogh M; Fischer S; Vargha P; Lakatos PL Orv Hetil; 2006 Jan; 147(4):175-81. PubMed ID: 16515026 [TBL] [Abstract][Full Text] [Related]
33. Plasma levels of endothelin-1 in patients with Crohn's disease and ulcerative colitis. Letizia C; Boirivant M; De Toma G; Cerci S; Subioli S; Scuro L; Ferrari P; Pallone F Ital J Gastroenterol Hepatol; 1998 Jun; 30(3):266-9. PubMed ID: 9759593 [TBL] [Abstract][Full Text] [Related]
34. Plasma total homocysteine in the active stage of ulcerative colitis. Drzewoski J; Gasiorowska A; Małecka-Panas E; Bald E; Czupryniak L J Gastroenterol Hepatol; 2006 Apr; 21(4):739-43. PubMed ID: 16677162 [TBL] [Abstract][Full Text] [Related]
35. Leukemia inhibitory factor involvement in human ulcerative colitis and its potential role in malignant course. Guimbaud R; Abitbol V; Bertrand V; Quartier G; Chauvelot-Moachon L; Giroud J; Couturier D; Chaussade DC Eur Cytokine Netw; 1998 Dec; 9(4):607-12. PubMed ID: 9889404 [TBL] [Abstract][Full Text] [Related]
36. Ileostomy carcinomas a review: the latent risk after colectomy for ulcerative colitis and familial adenomatous polyposis. Quah HM; Samad A; Maw A Colorectal Dis; 2005 Nov; 7(6):538-44. PubMed ID: 16232232 [TBL] [Abstract][Full Text] [Related]
37. Aberrant crypt foci as precursors of the dysplasia-carcinoma sequence in patients with ulcerative colitis. Kukitsu T; Takayama T; Miyanishi K; Nobuoka A; Katsuki S; Sato Y; Takimoto R; Matsunaga T; Kato J; Sonoda T; Sakamaki S; Niitsu Y Clin Cancer Res; 2008 Jan; 14(1):48-54. PubMed ID: 18172251 [TBL] [Abstract][Full Text] [Related]